The Joint Committee on Drugs Use Final Report could herald the biggest shake up of drug laws in the history of the Irish state

Drug Policy In Ireland: Beyond Analysis Paralysis and Consultation Fatigue

The Joint Committee on Drugs Use Final Report, launched at Leinster House this morning, should be warmly welcomed. It is a serious piece of cross-party work, and it arrives at an important moment for Irish drug policy.

The report considers the recommendations of the Citizens’ Assembly on Drugs Use as part of a wider democratic process. Among its broad ranging recommendations, it sets out clearly that drug use should be approached as a public health issue. It also supports the view that personal possession should no longer be treated as a criminal matter.

To understand the significance of the report, it is worth placing it in the wider policy landscape into which it now lands.

Ireland has had a stated health-led approach to drug use since the publication of Reducing Harm, Supporting Recovery, the National Drugs Strategy, in 2017. In the years since, Ireland has produced a substantial body of work:

Report of the Working Group to Consider Alternative Approaches to the Possession of Drugs for Personal Use (2019)

Mid-term Review of the National Drugs Strategy (2021)

Citizens’ Assembly on Drugs Use (2024)

Joint Committee Interim Report on the Citizens’ Assembly Recommendations (2024)

Independent Evaluation of the National Drugs Strategy (2025)

Draft Successor National Drugs Strategy and Public Consultation (2026)…yet to be finalised/published

And today’s:

Joint Committee on Drugs Use Final Report on the Citizens’ Assembly Recommendations (2026)

The policy architecture is substantial. The paperwork is not the issue. The issue is implementation.

Consider one example. Legislation to allow supervised injecting facilities was signed into law by the President of Ireland in May 2017. Ireland’s first such facility opened, over seven years later, at Merchants Quay in Dublin in December 2024.

Internationally, drug policy is increasingly shaped by questions of security. Against that backdrop, it is significant that the Joint Committee’s report reaffirms the importance of prevention, harm reduction, treatment, recovery and dignity; not just as stated values, but as elements that must be reflected in how policy is implemented in practice, in law, in funding and in accountability.

The next task is to ensure that this health led ambition is carried through into delivery: in services on the ground, in access to care, and in the everyday experience of people who use drugs, their families and their communities.

The report is also welcome because it pays attention to people whose needs have too often been treated as secondary; women, young people, families, kinship carers, marginalised communities and neurodiverse people. It recognises that people do not encounter drug use, addiction or the State on equal terms.

The strength of the report is that it brings these strands together and turns them towards delivery.

Ireland has spent years debating what a health-led approach should look like. We have consulted, reviewed, debated and consulted again. The value of this report is that it does not simply add another layer of discussion. It points towards practical steps that could be taken.

The report is detailed and grounded in practical recommendations. It points to a range of concrete steps. For example, it supports a shift away from criminalisation for personal possession, expanded access to long acting injectable buprenorphine, wider availability of naloxone, including in prisons, and the development of drug consumption rooms building on the experience at Merchants Quay Ireland’s Supervised Injecting Facility. It’s full of recommendations that can improve the quality of lives of people who use drugs, their families and their communities.

Significantly, the Committee is calling for a standing Joint Oireachtas Committee on Drug Use and Related Issues. Not another time limited process, but a permanent mechanism with a mandate to scrutinise implementation over time.

This report is not a Government document. It is the product of a cross-party committee, government and opposition members working together. That breadth matters. Perhaps the most significant example is an earlier interim report, produced by a committee formed under the previous government, which recommended the repeal of Section 3 of the Misuse of Drugs Act 1977, the law that makes personal possession of drugs a criminal offence. Today's report, from a committee formed under the current government, has not only kept that recommendation but built upon it. On one of the most contested questions in drug policy, two committees formed under two different governments have reached the same conclusion.

The report now sits with Government, which will consider its recommendations and set out its response in the period ahead. That process is important, but it also carries a familiar risk.

We should not allow this to become another cycle where good analysis is produced, politely received and then slowly loses momentum. The opportunity now is to carry the report’s ambition through into practical, measurable implementation.

The question now is simple, and hard.

Can Ireland protect the intention of reform through implementation; with clear leadership, timelines, resourcing and accountability? That will depend on the decisions taken in the months ahead.

Tony Duffin is a recognised public health and social policy leader and expert with over 30 years’ experience across Ireland, Europe and internationally. His work focuses on drug policy, service design and delivery, and harm reduction. He is co-host of Dealing With Drugs: A Hot Press Podcast